Alkem Laboratories Limited (NSE:ALKEM)
India
· Delayed Price · Currency is INR | Market Cap | 575.47B |
| Revenue (ttm) | 129.65B |
| Net Income (ttm) | 21.65B |
| Shares Out | 119.57M |
| EPS (ttm) | 181.11 |
| PE Ratio | 26.58 |
| Forward PE | 24.53 |
| Dividend | 45.00 (0.92%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 63,332 |
| Average Volume | 240,813 |
| Open | 4,840.00 |
| Previous Close | 4,813.00 |
| Day's Range | 4,775.00 - 4,847.50 |
| 52-Week Range | 4,491.65 - 6,439.90 |
| Beta | 0.42 |
| RSI | 36.55 |
| Earnings Date | Aug 8, 2025 |
About Alkem Laboratories
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also p... [Read more]
Financial Performance
In 2024, Alkem Laboratories's revenue was 129.65 billion, an increase of 2.34% compared to the previous year's 126.68 billion. Earnings were 21.65 billion, an increase of 20.59%.
Financial StatementsNews
Alkem Labs shares trade lower after Rs 856 crore block deal
Shares of Alkem Laboratories came into focus on Tuesday following a large block deal worth ₹856.39 crore executed on the BSE. The transaction involved the exchange of approximately 17.49 lakh shares a...
Alkem Labs in focus as promoter Jayanti Sinha to sell 1.42 percent stake via Rs 825 crore block deal
Shares of Alkem Laboratories will be in focus today as a large block deal is expected on the counter. According to deal terms, promoter entity Jayanti Sinha is likely to sell a 1.42 percent stake in t...
Stocks to watch on May 30: Bajaj Auto, Ola Electric, Samvardhana Motherson, Suzlon, Alkem Labs in focus after key brokerage calls
Brokerage firms released fresh research notes on select Indian stocks ahead of market action on May 30. The reports cover Q4FY25 earnings trends, management commentary, and sector outlook across auto,...
Nomura maintains ‘Buy’ on Alkem Labs; expects Semaglutide launch to drive future growth
Nomura has reiterated its Buy rating on Alkem Labs with a target price of ₹5,430, viewing the Q4FY25 earnings as largely in line on sales, though EBITDA and PAT came in 2% and 6% below estimates, resp...
Jefferies maintains ‘Underperform’ on Alkem Labs and cuts target price to Rs 4,460 on margin concerns
Jefferies has maintained its Underperform rating on Alkem Labs and cut its target price to ₹4,460 after the company’s Q4 earnings missed estimates on lower margins. After 18 months of margin improveme...
Stocks in focus on May 29: Bajaj Auto, Suzlon Energy, Alkem Labs, SJVN among 40 firms to report Q4 results
As the Q4FY25 earnings season nears its conclusion, Thursday, May 29, will be a key day for several mid- and large-cap companies. A total of 40 listed firms are scheduled to release their quarterly fi...
Alkem Laboratories to acquire 100% stake in Bombay Ortho Industries
Alkem Laboratories has announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has signed a definitive agreement to acquire a 100% stake in Bombay Ortho Industries Private Limited. ...
Alkem Laboratories receives positive outcome from US FDA inspection at Taloja Bioequivalence Center
Alkem Laboratories Ltd announced on March 13, 2025, that the US Food and Drug Administration (US FDA) has successfully completed an inspection at the company’s Bioequivalence Center in Taloja, Maharas...
Alkem Laboratories launches affordable generic empagliflozin in India
Alkem Laboratories Ltd has launched Empanorm, a generic version of empagliflozin, at prices nearly 80% lower than innovator products. Empagliflozin is a widely used SGLT-2 inhibitor for managing type-...
Nomura upgrades Alkem Labs to Buy and believes that concerns around growth are in price
Nomura has upgraded Alkem Labs to a Buy rating but has revised its target price down to ₹5,430.
Alkem Laboratories Ltd (BOM:539523) Q3 2025 Earnings Call Highlights: Strategic Acquisitions ...
Alkem Laboratories Ltd (BOM:539523) Q3 2025 Earnings Call Highlights: Strategic Acquisitions and Market Share Expansion Amidst Challenges
Q3 2025 Alkem Laboratories Ltd Earnings Call Transcript
Q3 2025 Alkem Laboratories Ltd Earnings Call Transcript
Alkem Laboratories acquires 100% stake in Adroit Biomed for Rs 140 crore
Alkem Laboratories Limited announced the acquisition of a 100% stake in Adroit Biomed Limited through a binding term sheet on February 7, 2025. The deal is valued at Rs 140 crore, payable in two tranc...
Alkem Laboratories shares drop 3% as revenue growth remains flat at Rs 3374 crore in Q3
Alkem Laboratories Limited saw its shares drop over 3% following the announcement of its Q3 FY25 results. As of 2:05 PM, the shares were trading 2.30% lower at Rs 5,134.70. The pharmaceutical company ...
Alkem Laboratories Q3 FY25 Results: Revenue flat at Rs 3374 crore, Profit up 6% YoY
Alkem Laboratories Limited reported its Q3 FY25 financial results, highlighting modest growth in revenue and profitability, supported by operational efficiencies. Key Highlights – Q3 FY25 (YoY Compari...
Alkem Laboratories launches Kojiglo serum for facial hyperpigmentation in India
Alkem Laboratories Ltd., a leader in healthcare solutions, has launched the Kojiglo serum in India, designed to effectively manage facial hyperpigmentation. This innovative product is the first of its...
Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84%
The pharmaceutical sector exhibited a mix of gains and losses in early trading. Here’s a detailed overview: Gainers: Glenmark Pharmaceuticals surged +1.57%, trading at ₹1,527.20. GlaxoSmithKline (Glax...
Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline
Pharma stocks showed mixed trends in early trading as of 9:24 AM today. Biocon led the gainers, rising 4.41% to trade at ₹381.30, while Mankind Pharma climbed 1.85%, trading at ₹2,644.05. Top Gainers:...
Alkem Laboratories sells Pithampur manufacturing facility to Rubicon Research Rs 149 crore
Alkem Laboratories Ltd. has announced the sale of its Pithampur manufacturing facility to Rubicon Research Ltd. for INR 149 crores. This transaction is being carried out on a slump sale basis, as per ...
Alkem Laboratories to transfer trade generics business to Alkem Wellness for Rs 750 crore
Alkem Laboratories has recently informed exchanges that the company will transfer its trade generics business to its subsidiary, Alkem Wellness Ltd., for up to ₹750 crore. In FY24, this business gener...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
BofA flags structural risks in domestic pharma; maintains ‘Underperform’ on Mankind and Alkem, ‘Neutral’ on Torrent Pharma
Bank of America (BofA) has raised concerns about structural challenges in the domestic pharmaceutical sector, citing margin risks from slowing volume growth and unaccounted regulatory pricing pressure...
Jefferies maintains underperform on Alkem Labs with target at ₹4,950, indicating 11.1% downside
Jefferies has maintained its Underperform rating on Alkem Laboratories with a target price of ₹4,950, suggesting an 11.1% downside from the current market price (CMP) of ₹5,565.15. The company’s Q2 re...
Nomura on Alkem Labs: Maintains Neutral call, raises target, expects 9.6% upside to Rs 6,097
Nomura has maintained a Neutral rating on Alkem Labs, with a revised target price of ₹6,097 per share, reflecting a 9.6% increase from the current market price (CMP) of ₹5,565.15. The company anticipa...
Alkem Laboratories Q2 FY25 Results: Revenue up 0.7% YoY to ₹3,414.67, Net Profit up 14.2% YoY
Alkem Laboratories Q2 FY25 Financial Results Highlights: Revenue from Operations: Quarter-over-Quarter (QoQ): Revenue rose to ₹3,414.67 crore in Q2 FY25 from ₹3,031.82 crore in Q1 FY25. Year-over-Year...